Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking for Charity - 2006 -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (239)	1/8/2006 12:41:04 AM
From: tuck	Respond to of 592

Thanks to John for supplying the prices and some of the formatting . . . my portfolio numbers after dropping APBI to get to 100% allocation from 105%. I made that choice without looking at its recent performance, because it was one I didn't know as well as the others; I may regret that decision, as it apparently has started nicely. Allocation # Shares $ Invested Price AGIX 5% 250 5000 20.01 ARQL 5% 817 5000 6.12 CRIS 5% 1404 5000 3.56 CRXX 5% 611 5000 8.18 CVTX 10% 404 10000 24.73 DSCO 15.0% 2246 15000 6.68 GNVC 5% 3030 5000 1.65 MDCO 10% 573 10000 17.45 MOGN 10% 583 10000 17.16 MSHL 5% 800 5000 6.25 NKTR 5% 304 5000 16.46 TELK 15.0% 883 15000 16.99 XGEN 5% 1587 5000 3.15 Since I own a number of these in real life, I'm happy to see them off to a decent start, even if I'm not in the top 5. No more sulking, anyone, at least not till it's over. We have seen no instances that I can remember of someone starting strong and holding on to win. The qualifier "that I can remember" is an important one, as my memory is embarrassingly fallible, and I won't claim to have checked. Cheers, Tuck

To: tuck who wrote (239)	1/10/2006 10:00:38 AM
From: nigel bates	Respond to of 592

Let's just drop APBI, then Ouch ! Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI - News), and its subsidiary, Biovest International, Inc. (OTCBB:BVTI - News), jointly reported long-term follow-up data from its Phase 2 clinical trial of BiovaxID(TM), a personalized vaccine for follicular lymphoma, during a poster session at the 47th Annual Meeting of the American Society of Hematology in Atlanta, December 11, 2005 . (Abstract #2441) In this single-arm, Phase 2 study, patients with follicular B-cell Non-Hodgkin's Lymphoma (NHL) in continuous first clinical remission six months following PACE chemotherapy were treated with a series of subcutaneous vaccinations of BiovaxID. BiovaxID is comprised of tumor-derived Id protein (tumor antigen) conjugated to KLH as a carrier protein administered with GM-CSF (granulocyte macrophage colony stimulating factor). With a median follow-up of 9.2 years, 45 percent of patients remained in continuous first clinical remission at their most recent follow-up (either in 2004-2005), and the overall survival rate was 95 percent. Furthermore, median disease free survival for the patient cohort was 96.5 months (8.0 years). Based on historical data these results suggest a clinically significant advance over current expectations of disease progression. "The results of this Phase 2 study compare very favorably with chemotherapy alone and with CHOP-R where the median disease-free-survival is 2.2 years and 6.9 years respectively. The ongoing Phase 3 trial of BiovaxID vs. non-specific immune stimulation should help to clarify the role of vaccine therapy in patients with follicular lymphoma," said Barry Gause, M.D., co-investigator for the clinical trial at the National Cancer Institute (NCI). "We are encouraged by these long term follow-up data from our Phase 2 study," said Angelos Stergiou, M.D., Director of Product Development, Accentia Biopharmaceuticals. "These results underscore the potential of BiovaxID(TM) as a promising personalized therapeutic vaccine for follicular lymphoma. Patients, physicians, and payors are understandably requesting that, at some point in the battle against cancer, expensive cancer therapeutics need to start to provide cures. Because this disease is considered incurable with existing therapies we are particularly pleased with the reported rate of overall survival without tumor recurrence, which is the gold standard for cancer therapeutics." BiovaxID is designed to evoke the power of each patient's immune system, priming it to recognize and eliminate cancerous lymphoma cells, while sparing normal B-cells. BiovaxID uses complete high fidelity copies of each patient's unique tumor antigen produced in a hybridoma cell line exclusively licensed from Stanford University. Other vaccines currently being evaluated for the treatment of follicular lymphoma are made by molecular cloning and splicing, and incorporate only a portion of the patient's tumor antigen. Background on immunotherapeutics for non-Hodgkin's lymphoma Rituxan is a passive immunotherapeutic consisting of a monoclonal antibody administered intravenously. The monoclonal antibody is directed to an antigen (CD20) present on all B-lymphocytes. Accordingly, Rituxan promotes the elimination of cancerous and normal B-lymphocytes bearing this antigen. Rituxan therapy is typically repeated as necessary at intervals in order to control the lymphoma. Annual sales for Rituxan are about $1.5B. BiovaxID is an active immunotherapeutic which stimulates the production of anti-tumor antibodies and induces a cell-mediated immune response to cancerous B-lymphocytes but not to normal B-lymphocytes. As an active immunotherapeutic, BiovaxID may also provide ongoing immunosurveillance for recurrent tumors. About Accentia Biopharmaceuticals, Inc. Accentia Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of late-stage clinical products in the therapeutic areas of respiratory disease and oncology. Two of these products are SinuNase(TM) and BiovaxID. The Company's SinuNase(TM) product, in development to treat chronic sinusitis (rhinosinusitis), is a novel application and formulation of a known anti-fungal licensed from the Mayo Foundation for Medical Education and Research. BiovaxID is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkins' lymphoma. BiovaxID, which is being developed by Accentia's subsidiary Biovest International, Inc., is currently in a Phase 3 clinical trial. In addition, Accentia's growing specialty pharmaceutical business, TEAMM Pharmaceuticals, has a portfolio of currently marketed products plus a pipeline of additional products under development by third parties. For further information, please visit our web site: www.accentia.net About Biovest International Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and for clinical trials. In addition, Biovest develops, manufactures, and markets patented cell culture systems, including the AutovaxID(TM), which is being developed as an automated vaccine manufacturing instrument. Biovest's therapy for follicular non-Hodgkin's lymphoma is currently in a Phase 3 pivotal clinical trial at over 20 major centers in the U.S. being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute. For further information, please visit Biovest's website: biovest.com.

To: tuck who wrote (239)	1/27/2006 7:56:37 AM
From: John McCarthy	Respond to of 592

tuck - fyi Press Release Source: GenVec, Inc. Long-Term Survival Data from Genvec's Phase II Study of TNFerade(TM) in Esophageal Cancer Presented at ASCO GI Friday January 27, 7:00 am ET Survival Profile Compares Favorably with Recent Studies GAITHERSBURG, Md.--(BUSINESS WIRE)--Jan. 27, 2006--GenVec, Inc. (Nasdaq:GNVC - News) announced today that Dr. Neil Senzer, Medical Director of the Mary Crowley Research Center, located in Dallas, Texas, has presented long-term follow-up data on the Phase II study of GenVec's investigational oncology drug, TNFerade, at the American Society of Clinical Oncology's Gastroenterological Cancer Symposium, currently in session in San Francisco. In oral and poster presentations, Dr. Senzer discussed results from a regimen in which 24 patients with locally advanced, resectable esophageal cancer were treated prior to surgery with chemotherapy, radiation, and TNFerade injections to the tumor in doses ranging from 4x10e8 p/u to 4x10e11 p/u. Esophageal cancer is a difficult to treat disease, and only modest progress has been made in patient survival post-diagnosis during the past decade. After one year, 88% of the Phase II study patients were alive, which compares favorably with the average one-year survival of 52% reported in six comparable recent studies. Seven of the surviving patients have been followed out past 24 months. The two-year survival percentage for all dosage levels of TNFerade combined is currently 73%, with follow-up continuing. The average two-year survival percentage reported in five comparable recent studies was 33%. The median survival point for all patients in GenVec's study has not yet been reached, with follow-up ranging from 16 to 34 months. "TNFerade has been tested in a wide variety of cancers and continues to show promising indications of activity even in some of the more difficult to treat solid tumors such as esophageal and pancreatic cancer," said Thomas A. Davis, M.D., GenVec's Chief Medical Officer. GenVec is currently conducting a multi-center Phase II trial with TNFerade in locally advanced pancreatic cancer (the PACT Study), a Phase II trial in rectal cancer in collaboration with the National Cancer Institute, and a Phase II trial in metastatic melanoma. GenVec, Inc. is a biopharmaceutical company focused on the development of TNFerade for cancer. Additional information on GenVec and its portfolio of product candidates is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission. The ASCO GI poster contains additional information relating to the Phase II esophageal study, including background information, objectives, study design, safety and efficacy results and conclusions. A copy of the poster presentation can be found on GenVec's website by selecting Webcasts & Data/Recent Data Presentations/Esophageal Cancer. Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future programs and studies, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; the timing and content of future U.S. Food and Drug Administration regulatory actions with respect to GenVec, its product candidates, or collaborators, risks relating to the commercialization, if any, of GenVec's proposed product candidates (such as marketing, regulatory, patent, product liability, supply, competition and other risks); dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements. biz.yahoo.com